Literature DB >> 10749663

Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

P J Tacken1, F D Beer, L C Vark, L M Havekes, M H Hofker.   

Abstract

The apolipoprotein (apo)E receptor 2 (apoER2) is a recently cloned member of the low-density lipoprotein (LDL) receptor (LDLR) family, showing a high homology with both the LDLR and the very-low-density lipoprotein (VLDL) receptor (VLDLR). In the present study, the binding characteristics of the apoER2 with respect to apoE and lipoprotein lipase (LPL) were investigated. VLDL was isolated from both apoE-deficient mice and mice expressing the human APOE2 (Arg(158)-->Cys) and APOE3-Leiden isoforms on an Apoe(-/-),Ldlr(-/-) double knock-out background. apoE-rich rabbit beta-VLDL was used as a positive control for binding. Binding experiments performed with Chinese hamster ovary cells expressing the human apoER2 showed that the receptor was able to bind VLDL containing either of the apoE isoforms, as well as the apoE-deficient VLDL. Hence, in contrast with the VLDLR, the apoER2 is not strictly dependent on apoE for VLDL binding. Since LPL has been shown to enhance the binding of lipoproteins to several members of the LDLR family, including the LDLR-related protein, VLDL receptor, gp330 and the LDLR itself, VLDL binding experiments were performed in the presence of LPL. Addition of LPL resulted in a significant increase in apoER2 binding for all VLDL fractions used in this study. In conclusion, lipoprotein binding of VLDL to the apoER2 is enhanced in the presence of LPL, and is not restricted to apoE-containing lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749663      PMCID: PMC1220966          DOI: 10.1042/0264-6021:3470357

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain.

Authors:  D H Kim; H Iijima; K Goto; J Sakai; H Ishii; H J Kim; H Suzuki; H Kondo; S Saeki; T Yamamoto
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

2.  Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center.

Authors:  S Salinelli; J Y Lo; M P Mims; E Zsigmond; L C Smith; L Chan
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

3.  Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro.

Authors:  J D Medh; S L Bowen; G L Fry; S Ruben; M Andracki; I Inoue; J M Lalouel; D K Strickland; D A Chappell
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

4.  A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse.

Authors:  S Novak; T Hiesberger; W J Schneider; J Nimpf
Journal:  J Biol Chem       Date:  1996-05-17       Impact factor: 5.157

5.  The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase.

Authors:  A Nykjaer; G Bengtsson-Olivecrona; A Lookene; S K Moestrup; C M Petersen; W Weber; U Beisiegel; J Gliemann
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

6.  The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.

Authors:  K M Argraves; F D Battey; C D MacCalman; K R McCrae; M Gåfvels; K F Kozarsky; D A Chappell; J F Strauss; D K Strickland
Journal:  J Biol Chem       Date:  1995-11-03       Impact factor: 5.157

7.  Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3.

Authors:  S Takahashi; K Oida; M Ookubo; J Suzuki; M Kohno; T Murase; T Yamamoto; T Nakai
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

8.  The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP.

Authors:  S E Williams; I Inoue; H Tran; G L Fry; M W Pladet; P H Iverius; J M Lalouel; D A Chappell; D K Strickland
Journal:  J Biol Chem       Date:  1994-03-25       Impact factor: 5.157

9.  Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor.

Authors:  P K Frykman; M S Brown; T Yamamoto; J L Goldstein; J Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

10.  Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor.

Authors:  K Kobayashi; K Oka; T Forte; B Ishida; B Teng; K Ishimura-Oka; M Nakamuta; L Chan
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

View more
  7 in total

Review 1.  Lipoprotein lipase in the brain and nervous system.

Authors:  Hong Wang; Robert H Eckel
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

2.  Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.

Authors:  Esther M M Ooi; Betsy S Russell; Eric Olson; Sam Z Sun; Margaret R Diffenderfer; Alice H Lichtenstein; Leonard Keilson; P Hugh R Barrett; Ernst J Schaefer; Dennis L Sprecher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-17       Impact factor: 8.311

3.  N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.

Authors:  Zhenyu Sheng; Mary Prorok; Brigid E Brown; Francis J Castellino
Journal:  Neuropharmacology       Date:  2008-05-24       Impact factor: 5.250

4.  Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate.

Authors:  Yang Gao; Wei Shen; Boyu Lu; Qingjiong Zhang; Yang Hu; Ying Chen
Journal:  J Lipid Res       Date:  2014-06-04       Impact factor: 5.922

5.  A Subregion of Reelin Suppresses Lipoprotein-Induced Cholesterol Accumulation in Macrophages.

Authors:  Emmanuel U Okoro; Hongfeng Zhang; Zhongmao Guo; Fang Yang; Carlie Smith; Hong Yang
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.

Authors:  Mohammad Zarei; Emma Barroso; Xavier Palomer; Jianli Dai; Patricia Rada; Tania Quesada-López; Joan Carles Escolà-Gil; Lidia Cedó; Mohammad Reza Zali; Mahsa Molaei; Reza Dabiri; Santiago Vázquez; Eugènia Pujol; Ángela M Valverde; Francesc Villarroya; Yong Liu; Walter Wahli; Manuel Vázquez-Carrera
Journal:  Mol Metab       Date:  2017-12-19       Impact factor: 7.422

7.  SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1α-LIPIN 1 pathway and increasing CD36 through Nrf2.

Authors:  Emma Barroso; Rosalía Rodríguez-Rodríguez; Mohammad Zarei; Javier Pizarro-Degado; Anna Planavila; Xavier Palomer; Francesc Villarroya; Manuel Vázquez-Carrera
Journal:  Cell Commun Signal       Date:  2020-09-10       Impact factor: 5.712

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.